CIK 0001597264
BPMC Blueprint Medicines Corp
Insider trading from SEC Form 4. Last filing Jul 21, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
18
with a Form 4 at this company
Signals
Open-market buys and sells at Blueprint Medicines Corp, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 34Weak | Percy H. Carter CHIEF SCIENTIFIC OFFICER sell | $135k 1,051 shares | -2% | - | |
| 39Weak | Christina Rossi CHIEF OPERATING OFFICER sell | $150k 1,172 shares | -2% | - | |
| 38Weak | Percy H. Carter CHIEF SCIENTIFIC OFFICER sell | $340k 2,659 shares | -5% | - | |
| 13Weak | Jeffrey W. Albers director sell | $506k 5,000 shares | -3% | - | |
| 28Weak | Christina Rossi CHIEF OPERATING OFFICER sell | $229k 2,274 shares | -3% | - | |
| 7Weak | Ariel Hurley PRINCIPAL ACCOUNTING OFFICER sell | $284k 2,752 shares | -14% | - | |
| 21Weak | Christina Rossi CHIEF OPERATING OFFICER sell | $231k 2,274 shares | -3% | - | |
| 25Weak | Kate Haviland CHIEF EXECUTIVE OFFICER sell | $216k 2,498 shares | -1% | - | |
| 27Weak | Christina Rossi CHIEF OPERATING OFFICER sell | $216k 2,274 shares | -3% | - | |
| 48Moderate | Jeffrey W. Albers director sell | $512k 5,766 shares | -4% | - | |
| 15Weak | Jeffrey W. Albers director sell | $659k 7,500 shares | -5% | - | |
| 44Moderate | Percy H. Carter CHIEF SCIENTIFIC OFFICER sell | $313k 3,530 shares | -6% | - | |
| 47Moderate | Debra Durso-Bumpus CHIEF PEOPLE OFFICER sell | $458k 5,157 shares | -9% | - | |
| 65Notable | Kate Haviland CHIEF EXECUTIVE OFFICER sell | $1.4M 16,151 shares | -9% | - | |
| 40Moderate | Ariel Hurley PRINCIPAL ACCOUNTING OFFICER sell | $118k 1,326 shares | -7% | - | |
| 54Moderate | Michael Landsittel CHIEF FINANCIAL OFFICER sell | $469k 5,284 shares | -7% | - | |
| 45Moderate | Philina Lee CHIEF COMMERCIAL OFFICER sell | $331k 3,733 shares | -8% | - | |
| 47Moderate | Tracey L McCain EVP AND CHIEF LEGAL OFFICER sell | $467k 5,262 shares | -7% | - | |
| 54Moderate | Fouad Namouni PRESIDENT, R & D sell | $576k 6,489 shares | -8% | - | |
| 54Moderate | Christina Rossi CHIEF OPERATING OFFICER sell | $577k 6,495 shares | -8% | - | |
| 38Weak | L. Becker Hewes CHIEF MEDICAL OFFICER sell | $891k 10,095 shares | -25% | - | |
| 29Weak | Ariel Hurley PRINCIPAL ACCOUNTING OFFICER sell | $297k 3,203 shares | -15% | - | |
| 27Weak | Christina Rossi CHIEF OPERATING OFFICER sell | $216k 2,274 shares | -3% | - | |
| 20Weak | Jeffrey W. Albers director sell | $1.7M 15,161 shares | -9% | - | |
| 28Weak | Christina Rossi CHIEF OPERATING OFFICER sell | $250k 2,274 shares | -3% | - | |
| 31Weak | Kate Haviland CHIEF EXECUTIVE OFFICER sell | $159k 1,446 shares | -1% | - | |
| 13Weak | Jeffrey W. Albers director sell | $511k 5,000 shares | -3% | - | |
| 12Weak | Ariel Hurley PRINCIPAL ACCOUNTING OFFICER sell | $225k 2,250 shares | -13% | - | |
| 20Weak | Jeffrey W. Albers director sell | $1.3M 15,000 shares | -9% | - | |
| 27Weak | Christina Rossi CHIEF OPERATING OFFICER sell | $218k 2,274 shares | -3% | - | |
| 11Weak | Ariel Hurley PRINCIPAL ACCOUNTING OFFICER sell | $170k 1,819 shares | -11% | - | |
| 33Weak | Kate Haviland CHIEF EXECUTIVE OFFICER sell | $227k 2,353 shares | -2% | - | |
| 27Weak | Christina Rossi CHIEF OPERATING OFFICER sell | $216k 2,274 shares | -3% | - | |
| 40Moderate | Lonnel Coats director sell | $1.9M 19,824 shares | -90% | - | |
| 6Weak | Jeffrey W. Albers director sell | $510k 5,000 shares | -3% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 17, 2025 | Alexis Borisy director | DDisposition to issuer Common Stock | -3,902 | - | - | 74,160 | Jul 21, 2025 |
| Jul 17, 2025 | Philina Lee Chief Commercial Officer | AGrant or award Common Stock | +21,353 | - | - | 63,349 | Jul 21, 2025 |
| Jul 17, 2025 | Tracey L McCain EVP & Chief Legal Officer | AGrant or award Common Stock | +21,353 | - | - | 88,195 | Jul 21, 2025 |
| Jul 17, 2025 | Percy H. Carter Chief Scientific Officer | AGrant or award Common Stock | +21,353 | - | - | 74,508 | Jul 21, 2025 |
| Jul 17, 2025 | Lonnel Coats director | DDisposition to issuer Common Stock | -6,144 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Habib J Dable director | DDisposition to issuer Common Stock | -3,902 | - | - | 8,742 | Jul 21, 2025 |
| Jul 17, 2025 | Fouad Namouni PRESIDENT, R & D | AGrant or award Common Stock | +39,456 | - | - | 115,237 | Jul 21, 2025 |
| Jul 17, 2025 | Jeffrey W. Albers director | DDisposition to issuer Common Stock | -5,777 | - | - | 144,755 | Jul 21, 2025 |
| Jul 17, 2025 | Michael Landsittel Chief Financial Officer | AGrant or award Common Stock | +21,353 | - | - | 94,277 | Jul 21, 2025 |
| Jul 17, 2025 | Christina Rossi Chief Operating Officer | AGrant or award Common Stock | +39,456 | - | - | 103,002 | Jul 21, 2025 |
| Jul 17, 2025 | Daniella Beckman director | DDisposition to issuer Common Stock | -3,902 | - | - | 10,842 | Jul 21, 2025 |
| Jul 17, 2025 | L. Becker Hewes Chief Medical Officer | AGrant or award Common Stock | +21,353 | - | - | 51,772 | Jul 21, 2025 |
| Jul 17, 2025 | Kate Haviland Chief Executive Officer | AGrant or award Common Stock | +129,210 | - | - | 295,139 | Jul 21, 2025 |
| Jul 17, 2025 | Debra Durso-Bumpus Chief People Officer | AGrant or award Common Stock | +21,353 | - | - | 70,959 | Jul 21, 2025 |
| Jul 17, 2025 | Mark Alan Goldberg director | DDisposition to issuer Common Stock | -3,902 | - | - | 18,254 | Jul 21, 2025 |
| Jul 17, 2025 | John Tsai director | DDisposition to issuer Common Stock | -3,902 | - | - | 8,742 | Jul 21, 2025 |
| Jul 17, 2025 | Lynn Seely director | DDisposition to issuer Common Stock | -3,902 | - | - | 13,254 | Jul 21, 2025 |
| Jul 17, 2025 | Ariel Hurley Principal Accounting Officer | AGrant or award Common Stock | +2,460 | - | - | 19,524 | Jul 21, 2025 |
| Jul 17, 2025 | Lynn Seely director | UTender of shares Common Stock | -13,254 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Habib J Dable director | UTender of shares Common Stock | -8,742 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Philina Lee Chief Commercial Officer | DDisposition to issuer Common Stock | -50,165 | - | - | 13,184 | Jul 21, 2025 |
| Jul 17, 2025 | Kate Haviland Chief Executive Officer | DDisposition to issuer Common Stock | -224,410 | - | - | 70,729 | Jul 21, 2025 |
| Jul 17, 2025 | Christina Rossi Chief Operating Officer | DDisposition to issuer Common Stock | -82,374 | - | - | 20,628 | Jul 21, 2025 |
| Jul 17, 2025 | Tracey L McCain EVP & Chief Legal Officer | DDisposition to issuer Common Stock | -51,103 | - | - | 37,092 | Jul 21, 2025 |
| Jul 17, 2025 | Daniella Beckman director | UTender of shares Common Stock | -10,842 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Percy H. Carter Chief Scientific Officer | DDisposition to issuer Common Stock | -56,614 | - | - | 17,894 | Jul 21, 2025 |
| Jul 17, 2025 | Debra Durso-Bumpus Chief People Officer | DDisposition to issuer Common Stock | -51,103 | - | - | 19,856 | Jul 21, 2025 |
| Jul 17, 2025 | Alexis Borisy director | UTender of shares Common Stock | -74,160 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | L. Becker Hewes Chief Medical Officer | DDisposition to issuer Common Stock | -50,165 | - | - | 1,607 | Jul 21, 2025 |
| Jul 17, 2025 | Lonnel Coats director | DDisposition to issuer Stock Option (Right to Buy)derivative | -11,818 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Fouad Namouni PRESIDENT, R & D | DDisposition to issuer Common Stock | -83,281 | - | - | 31,956 | Jul 21, 2025 |
| Jul 17, 2025 | Mark Alan Goldberg director | UTender of shares Common Stock | -18,254 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | John Tsai director | UTender of shares Common Stock | -8,742 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Michael Landsittel Chief Financial Officer | DDisposition to issuer Common Stock | -51,102 | - | - | 43,175 | Jul 21, 2025 |
| Jul 17, 2025 | Jeffrey W. Albers director | UTender of shares Common Stock | -144,755 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Ariel Hurley Principal Accounting Officer | DDisposition to issuer Common Stock | -16,146 | - | - | 3,378 | Jul 21, 2025 |
| Jul 17, 2025 | Philina Lee Chief Commercial Officer | UTender of shares Common Stock | -13,184 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Alexis Borisy director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | L. Becker Hewes Chief Medical Officer | UTender of shares Common Stock | -1,607 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Tracey L McCain EVP & Chief Legal Officer | UTender of shares Common Stock | -37,092 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Lynn Seely director | DDisposition to issuer Stock Option (Right to Buy)derivative | -21,818 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Kate Haviland Chief Executive Officer | UTender of shares Common Stock | -70,729 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Percy H. Carter Chief Scientific Officer | UTender of shares Common Stock | -17,894 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Habib J Dable director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,950 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Christina Rossi Chief Operating Officer | UTender of shares Common Stock | -20,628 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Lonnel Coats director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,909 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | John Tsai director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,950 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Jeffrey W. Albers director | DDisposition to issuer Stock Option (Right to Buy)derivative | -92,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Ariel Hurley Principal Accounting Officer | UTender of shares Common Stock | -3,378 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Michael Landsittel Chief Financial Officer | UTender of shares Common Stock | -43,175 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Fouad Namouni PRESIDENT, R & D | UTender of shares Common Stock | -31,956 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Daniella Beckman director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Debra Durso-Bumpus Chief People Officer | UTender of shares Common Stock | -19,856 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Mark Alan Goldberg director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,909 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Lonnel Coats director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,909 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Percy H. Carter Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -39,200 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Jeffrey W. Albers director | DDisposition to issuer Stock Option (Right to Buy)derivative | -170,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Alexis Borisy director | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,875 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | John Tsai director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,300 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Tracey L McCain EVP & Chief Legal Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -55,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Kate Haviland Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -2 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Philina Lee Chief Commercial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -8,650 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Lynn Seely director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,909 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | L. Becker Hewes Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,490 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Ariel Hurley Principal Accounting Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -2,250 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Christina Rossi Chief Operating Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -80,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Michael Landsittel Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Fouad Namouni PRESIDENT, R & D | DDisposition to issuer Stock Option (Right to Buy)derivative | -65,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Daniella Beckman director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,300 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Debra Durso-Bumpus Chief People Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -15,367 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Habib J Dable director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,300 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Mark Alan Goldberg director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Lonnel Coats director | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,875 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Alexis Borisy director | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Tracey L McCain EVP & Chief Legal Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Kate Haviland Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -591 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Percy H. Carter Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Philina Lee Chief Commercial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -6,928 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Jeffrey W. Albers director | DDisposition to issuer Stock Option (Right to Buy)derivative | -110,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Christina Rossi Chief Operating Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -6,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | L. Becker Hewes Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -26,125 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Michael Landsittel Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -26,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Ariel Hurley Principal Accounting Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | John Tsai director | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,570 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Fouad Namouni PRESIDENT, R & D | DDisposition to issuer Stock Option (Right to Buy)derivative | -26,125 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Debra Durso-Bumpus Chief People Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -30,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Habib J Dable director | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,570 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Mark Alan Goldberg director | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,875 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Lynn Seely director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,909 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Daniella Beckman director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,300 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Lonnel Coats director | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,188 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Daniella Beckman director | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,570 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | L. Becker Hewes Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,115 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Alexis Borisy director | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Kate Haviland Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -39,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Tracey L McCain EVP & Chief Legal Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -39,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Lynn Seely director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Jeffrey W. Albers director | DDisposition to issuer Stock Option (Right to Buy)derivative | -90,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Philina Lee Chief Commercial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -20,669 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | Christina Rossi Chief Operating Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -28,500 | - | - | 0 | Jul 21, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Jeffrey W. Albersdirector
- Daniella Beckmandirector, cfo, officer
- Alexis Borisydirector
- Lonnel Coatsdirector
- Percy H. CarterChief Scientific Officer
- Habib J Dabledirector
- Debra Durso-BumpusChief People Officer
- Mark Alan Goldbergdirector
- Kate HavilandChief Executive Officer
- L. Becker HewesChief Medical Officer
- Ariel HurleyPrincipal Accounting Officer
- Michael LandsittelChief Financial Officer
- Philina LeeChief Commercial Officer
- Tracey L McCainEVP & Chief Legal Officer
- Fouad NamouniPRESIDENT, R & D
- Christina RossiChief Operating Officer
- Lynn Seelydirector, ceo, president, officer
- John Tsaidirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.